Skip to main content
Terug
BIOVF logo

Swedish Orphan Biovitrum AB (publ)

Datakwaliteit: 100%
Overbought
BIOVF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 41,32
€ 0,00 (0,00%)
Marktkapitalisatie: 14,28B
Dagbereik
€ 41,32 € 41,32
52-Weeksbereik
€ 25,80 € 42,22
Volume
100
50D / 200D Gem.
€ 38,09 / € 33,40
Vorige Slotkoers
€ 41,32

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 30,0 0,4
P/B 0,4 2,9
ROE % 1,2 3,7
Net Margin % 1,7 3,8
Rev Growth 5Y % 16,1 10,0
D/E 0,3 0,2

Belangrijkste Punten

Revenue grew 16,05% annually over 5 years — strong growth
Earnings declined -87,73% over the past year
ROE of 1,22% is below average
Debt/Equity of 0,31 — conservative balance sheet
Generating 8,50B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,83%

Groei

Revenue Growth (5Y)
16,05%
Revenue (1Y)8,22%
Earnings (1Y)-87,73%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
1,22%
ROIC12,20%
Net Margin1,69%
Op. Margin28,50%

Veiligheid

Debt / Equity
0,31
Current Ratio0,90
Interest Coverage9,68

Waardering

P/E Ratio
29,96
P/B Ratio0,38
EV/EBITDA3,11
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8,22% Revenue Growth (3Y) 12,84%
Earnings Growth (1Y) -87,73% Earnings Growth (3Y) -55,51%
Revenue Growth (5Y) 16,05% Earnings Growth (5Y) -35,05%
Profitability
Revenue (TTM) 28,17B Net Income (TTM) 476,80M
ROE 1,22% ROA 0,71%
Gross Margin 43,63% Operating Margin 28,50%
Net Margin 1,69% Free Cash Flow (TTM) 8,50B
ROIC 12,20% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,31 Current Ratio 0,90
Interest Coverage 9,68 Dividend Yield 0,00%
Valuation
P/E Ratio 29,96 P/B Ratio 0,38
P/S Ratio 0,51 PEG Ratio -2,67
EV/EBITDA 3,11 Dividend Yield 0,00%
Market Cap 14,28B Enterprise Value 24,97B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 28,17B 26,03B 22,12B 18,79B 15,53B
Net Income 476,80M 3,89B 2,41B 2,64B 2,68B
EPS (Diluted) 1,38 11,24 7,39 8,44 8,62
Gross Profit 12,29B 20,24B 17,13B 14,01B 12,05B
Operating Income 8,03B 5,63B 4,07B 3,81B 3,73B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 67,26B 75,44B 74,03B 52,50B 48,66B
Total Liabilities 29,64B 35,15B 40,16B 25,97B 25,46B
Shareholders' Equity 37,62B 40,29B 33,87B 26,53B 23,20B
Total Debt 11,72B 16,74B 20,49B 9,10B 10,91B
Cash & Equivalents 1,04B 1,14B 904,00M 1,36B 1,05B
Current Assets 14,49B 13,16B 12,67B 11,21B 8,78B
Current Liabilities 16,03B 12,60B 19,10B 14,86B 8,76B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#103 of 1024
70
Custom Deep Value Investing (Seth Klarman)
#10 of 820
84
Growth Price/Sales Ratio Focus (Ken Fisher)
#233 of 616
43

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026